Navigating Challenges in Monitoring Chronic Myeloid Leukemia with Multiple BCR-ABL1 Transcripts

Brittany M. Smith, Diana Brewer, Brian J. Druker, Theodore P. Braun

Research output: Contribution to journalArticlepeer-review

Abstract

Quantitative PCR-based strategies are typically effective for monitoring BCR-ABL1 transcript levels in chronic myeloid leukemia (CML). Additionally, some patients treated with tyrosine kinase inhibitors can experience long-term treatment-free remission after discontinuation of the inhibitor. However, this outcome hinges on effectively monitoring the patient's response to therapy. We present a patient with CML and multiple BCR-ABL1 transcripts, including a rare isoform that lacks qPCR standardization. We describe unexpected discrepancies in transcript quantification, further having an impact on clinical decision-making regarding duration of treatment. To better inform clinical practice, we suggest monitoring patients at the same testing facility to better track transcript trend.

Original languageEnglish (US)
Pages (from-to)1707-1711
Number of pages5
JournalCase Reports in Oncology
Volume14
Issue number3
DOIs
StatePublished - Nov 29 2021

Keywords

  • BCR-ABL transcript
  • Chronic myeloid leukemia
  • Minimal residual disease
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Navigating Challenges in Monitoring Chronic Myeloid Leukemia with Multiple BCR-ABL1 Transcripts'. Together they form a unique fingerprint.

Cite this